Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3115)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2024 (publication date) through Mar 24, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| She WH, Cheung TT. Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma. World J Gastroenterol 2024; 30(18): 2479-2481 [PMID: 38764761 DOI: 10.3748/wjg.v30.i18.2479] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | She WH, Cheung TT. Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma. World J Gastroenterol 2024; 30(18): 2479-2481 [PMID: 38764761 DOI: 10.3748/wjg.v30.i18.2479] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v30/i18/2479.htm |
| Number | Citing Articles |
| 1 |
Asahiro Morishita, Kyoko Oura, Hiroki Tai, Rie Yano, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara. Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives. Cancers 2026; 18(4): 609 doi: 10.3390/cancers18040609
|
| 2 |
Yangyang Ou, Peng Yan, Tianyi Liang, Kang Chen, Bingfeng Lu, Yi Dai, Dalong Yang, Yiyu Chen, Haizhao Cao, Ming Yao, Junjiang Guo, Liang Liang, Jianjun Li, Yuanneng Nong, Ji ’an Chen, Fei Huang, Jian-Hong Zhong, Yihe Yan. Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma. European Journal of Radiology 2026; 199: 112784 doi: 10.1016/j.ejrad.2026.112784
|